Review Flashcards
CNI
TACROLIMUS
CYCLOSPORINE
ANTIPROLIFERATIVE AGENTS/ANTIMETABOLITES
AZATHIOPRINE
MYCOPHENOLATE MOFETIL
MYCOPHENOLATE SODIUM
MTOR INHIBITORS
SIROLIMUS
EVEROLIMUS
ANTIBODIES
ATGAM THYMOGLOBULIN BASILIXIMAB RITUXIMAB ATEMTUXUMAB IVIG
PROTEASOME INHIBITOR
BORTEZOMIB
POLYCLONAL ANTIBODIES MOA
T-CELL DEPLETION
CYTOTOXIC ACTIVITIES
MODULATION OF T CELL ACTIVATION
POLYCLONAL ANTIBODIES ADVERSE REACTIONS
CYTOKINE RELEASE SYNDROME LEUKOPENIA/THROMBOCYTOPENIA SERUM SICKNESS ANAPHYLAXIS INFECTION MALIGNANCIES-PTLD
POLYCLONAL ADVANTAGES
STRONGER, CAN BE USED TO TREAT REJECTION
POLYCLONAL DISADVANTAGES
ACUTE SIDE EFFETS
HIGHER INFECTION RATES
HIGHER MALIGNANCY RATES
MONOCLONAL ADVANTAGES
NO ACUTE SIDE EFFECTS
NOT ASSOCIATED WITH HIGH INFECTION OR MALIGNANCY RATES
MONOCLONAL DISADVANTAGES
WEAKER, CANNOT BE USED TO TREAT REJECTION
TACROLIMUS DOSING
0.1-0.15 MG/KG/DAY PO DIVIDED BID
CYCLOSPORINE MOA
INHIBITS FIRST PHASE OF T CELL ACTIVATION
REDUCES LEVEL OF CIRCULATING T CELLS
CYCLOSPORINE DOSING
5-10 MG/KG/DAY DIVIDED BID
CNI NEPHROTOXICITY
TAC=CYCLO
CNI HYPETENSION
CYCLO>TAC
CNI DM
TAC>CYCLO
CNI NEUROTOXICITY
TAC>CYCLO
CNI COSMETIC EFFECTS
CYCLO>TAC
CNI GI EFFECTS
TAC>CYCLO
CNI HYPERKALEMIA
TAC>CYCLO
CNI HLD
CYCLO>TAC
CNI LOW MAG
CYCLO=TAC
THINGS THAT INCREASE CNI LEVELS
- ZOLES
- MYCINS
- GRAPEFRUIT/POMEGRANATE JUICE
- DILT, VERAPAMIL, AMIO
- FLUOXETINE
- PROTEASE INHIBITORS
- REGLAN
- SIMEPRAVIR
THINGS THAT DECREASE CNI LEVEL
- MG/AL ANTACIDS
- KAYEXOLATE/OCTREOTIDE
- CHOLESTRYAMINE
- ANTI-EPILEPTICS
- RIFAMPIN
- NAFCILLINE
- ISONIAZID
- CARBAMEZEPINE
- HERBS (ST. JOHNS WART)
MTOR MOA
INHIBITS T CELL ACTIVATION AND PROLIFERATION
SIROLIMUS DOSING
6-12 MG LOADING DOSE
2-5 MG MAINTENANCE DOSE
SIROLIMUS/EVEROLIMUS SIDE EFFECTS
- NEUTROPENIA, THROMBOCYTOPENIA, LEUKOPENIA
- INCREASE ANEMIA
- HLD, HYPERTRIGLYCERIDEMIA
- DELAYED WOUND HEALING
- N/V/D
- MOUTH ULCERS
- INTERSTITIAL PNEUMONITIS
- THROMBOTIC MYCROANGIOGRAPHY
- PROTEINUREA
- LYMPHOCELE/LYMPHODEMA
- BONE PAIN
SIROLIMUS BLACK BOX WARNING
- HEPATIC ARTERY STENOSIS
- BRONCHIAL ANASTOMOTIC DEHISCENCE
EVEROLIMUS DOSING
0.75 MG PO BID
AZATHIOPRINE DOSING
1-3 MG/KG/DAY
AZATHIOPRINE MOA
INHIBIT PURINE SYNTHESIS
INHIBIT T CELL PROLIFERATION
AZATHIOPRINE DRUG INTERACTIONS
ALLOPURINON-> PANCYTOPENIA-> DEATH
MYCOPHENOLATE MOFETIL-> BONE MARROW SUPPRESSION. SEPERATE MEDS BY 24 HOURS
MYCOPHENOLATE MOFETIL MOA
INHIBIT PURINE SYNTHESIS
INHIBIT T AND B CELL PROLIFERATION
MYCOPHENOLATE SIDE EFFECTS
- N/V/D
- ANEMIA, THROMBOCYTOPENIA
- INFECTION
- GASTRITIS, GI BLEED
- CMV TISSUE INVASIVE DISEASE
- MALIGNANCY
MYCOPHENOLATE MOFETIL DURG INTERACTIONS
- ANTIVIRALS/SIROLIMUS-> INCREASED BONE MARROW SUPPORESSION
- CYCLOSPONINE-> DECREASED LEVELS OF MPA
- AZATHIOPRINE-> BONE MARROW SUPPRESSION. SEPERATE BY 24 HOURS
- CHOLESTYRAMINE-> LOWERS DRUG LEVEL
- AL/MG-> DECREASE ABSORPTION. SEPERATE BYT 2-4 HOURS
CORTICOSTEROIDS MOA
BLOCKS LYMPHOCYTE PROLIFERATIONS
ANTIINFLAMMATORY
METHYLPREDNISONE DOSING FOR REJECTION
250-1000 MG IV X 3 DAYS
CORTICOSTEROID SIDE EFFECTS
- EUPHORIA/DEPRESSION/MOOD DISORDERS
- HTN
- HBP
- HBS
- INFECTION
- MYOPATHY
- IMPAIRED WOUND HEALING
- HIRSUTISM
- ACNE
- WEIGHT GAIN/INCREASED APPETITE
- CUSHINGOID FACE
- OSTEOPOROSIS
PLASMAPHERESIS
MECHANICAL REMOVAL OF AB. DOES NOT DO ANYTHING TO THE B CELLS
IVIG DOSE
1-2 GM/KG
IVIG SIDE EFFECTS
- BACK PAIN
- HA
- FEVER/CHILLS
- BRONCHOSPASM
- HYPOTENSION
RITUXIMAB MOA
MONOCLONAL AB TARGETED AGAINST CD20 ANTIGEN ON B LYMPHOCYTES
RITUXIMAB DOSING
PREVENTION OF REJECTION- 375 MG/M2
TREATMENT OF REJECTION- 375 MG/M2
TREATMENT OF PTLD- 375 MG/M2/DOSE EVERY WEEK X 4 DOSES